Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback